Ultragenyx Pharmaceutical Inc.

RARE · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.4%

Institutions112.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$673.00M	$560.23M	$363.33M	$351.41M	$271.03M	$103.71M	$51.49M	$2.61M	$133000	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	–	$1.15M	$1000	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$535.00M	-$535.97M	-$648.92M	-$381.74M	-$330.12M	-$424.17M	-$371.37M	-$328.94M	-$248.01M	-$147.74M
Operating income as a percentage of revenue.	-79.5%	-95.7%	-178.6%	-108.6%	-121.8%	-409.0%	-721.2%	-12593.5%	-186471.4%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$575.00M	-$569.18M	-$707.42M	-$454.02M	-$186.57M	-$402.73M	-$197.61M	-$302.14M	-$245.87M	-$145.62M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-5.83	$-6.29	$-10.12	$-6.70	$-3.07	$-7.12	$-3.00	$-7.00	$-6.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-5.83	$-6.29	$-10.12	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$421.00M	$173.73M	$132.94M	$307.58M	$713.53M	$433.58M	$113.43M	$100.49M	$161.12M	$150000
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.53B	$1.50B	$1.55B	$1.52B	$1.76B	$1.14B	$719.56M	$490.75M	$540.63M	$559.57M
Everything the company owes — debt, unpaid bills, and other obligations.	$1.60B	$1.24B	$1.19B	$599.84M	$605.18M	$481.73M	$110.65M	$107.30M	$66.65M	$28.48M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$80.00M	$255.30M	$352.49M	$922.56M	$1.15B	$653.76M	$608.91M	$383.45M	$473.97M	-$284.66M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$466.00M	-$414.19M	-$380.46M	-$338.69M	-$132.22M	-$345.38M	-$290.57M	-$253.84M	-$160.97M	-$105.98M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$6.00M	$7.49M	$116.12M	$73.09M	$43.91M	$24.83M	$4.08M	$2.79M	$10.19M	$4.96M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$472.00M	-$421.68M	-$496.59M	-$411.79M	-$176.13M	-$370.21M	-$294.64M	-$256.64M	-$171.16M	-$110.93M

	You	Peer avg
Revenue Growth	+28.1%	+9800.0%
ROE	–	-37.4%

Ultragenyx Pharmaceutical Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison